Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

Weitzenfeld P, Bournazos S, Ravetch JV.

J Clin Invest. 2019 Aug 19. pii: 128437. doi: 10.1172/JCI128437. [Epub ahead of print]

2.

IgG Fc Receptors: Evolutionary Considerations.

Bournazos S.

Curr Top Microbiol Immunol. 2019 Feb 10. doi: 10.1007/82_2019_149. [Epub ahead of print]

PMID:
30739161
3.

A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Keeffe JR, Van Rompay KKA, Olsen PC, Wang Q, Gazumyan A, Azzopardi SA, Schaefer-Babajew D, Lee YE, Stuart JB, Singapuri A, Watanabe J, Usachenko J, Ardeshir A, Saeed M, Agudelo M, Eisenreich T, Bournazos S, Oliveira TY, Rice CM, Coffey LL, MacDonald MR, Bjorkman PJ, Nussenzweig MC, Robbiani DF.

Cell Rep. 2018 Nov 6;25(6):1385-1394.e7. doi: 10.1016/j.celrep.2018.10.031.

4.

Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Wang TT, Bournazos S, Ravetch JV.

Curr Opin Immunol. 2018 Aug;53:124-129. doi: 10.1016/j.coi.2018.04.026. Epub 2018 May 10. Review.

5.

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.

Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA.

Leukemia. 2018 Feb;32(2):547-549. doi: 10.1038/leu.2017.293. Epub 2017 Sep 19. No abstract available.

6.

Fcγ Receptor Function and the Design of Vaccination Strategies.

Bournazos S, Ravetch JV.

Immunity. 2017 Aug 15;47(2):224-233. doi: 10.1016/j.immuni.2017.07.009. Review.

7.

Diversification of IgG effector functions.

Bournazos S, Ravetch JV.

Int Immunol. 2017 Jul 1;29(7):303-310. doi: 10.1093/intimm/dxx025. Review.

8.

Signaling by Antibodies: Recent Progress.

Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV.

Annu Rev Immunol. 2017 Apr 26;35:285-311. doi: 10.1146/annurev-immunol-051116-052433. Review.

9.

Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis.

Raz A, Serrano A, Lawson C, Thaker M, Alston T, Bournazos S, Ravetch JV, Fischetti VA.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4781-4786. doi: 10.1073/pnas.1619249114. Epub 2017 Apr 20.

10.

Modulating IgG effector function by Fc glycan engineering.

Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3485-3490. doi: 10.1073/pnas.1702173114. Epub 2017 Mar 13.

11.

Attenuated Vaccines for Augmented Immunity.

Bournazos S, Ravetch JV.

Cell Host Microbe. 2017 Mar 8;21(3):314-315. doi: 10.1016/j.chom.2017.02.016.

12.

Anti-retroviral antibody FcγR-mediated effector functions.

Bournazos S, Ravetch JV.

Immunol Rev. 2017 Jan;275(1):285-295. doi: 10.1111/imr.12482. Review.

PMID:
28133801
13.

IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.

Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV.

Science. 2017 Jan 27;355(6323):395-398. doi: 10.1126/science.aai8128.

14.

The Role and Function of Fcγ Receptors on Myeloid Cells.

Bournazos S, Wang TT, Ravetch JV.

Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.MCHD-0045-2016. Review.

15.

Beyond Viral Neutralization.

Lewis GK, Pazgier M, Evans DT, Ferrari G, Bournazos S, Parsons MS, Bernard NF, Finzi A.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):760-764. doi: 10.1089/AID.2016.0299. Epub 2017 Feb 16. Review.

16.

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.

Sci Transl Med. 2016 Nov 30;8(367):367ra167.

17.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV.

Cell. 2016 Jun 16;165(7):1609-1620. doi: 10.1016/j.cell.2016.04.050.

18.

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Chakraborty AK, Nussenzweig MC.

Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.

19.

Fcγ receptor pathways during active and passive immunization.

Bournazos S, Ravetch JV.

Immunol Rev. 2015 Nov;268(1):88-103. doi: 10.1111/imr.12343. Review.

PMID:
26497515
20.

The role of Fc-FcγR interactions in IgG-mediated microbial neutralization.

Bournazos S, DiLillo DJ, Ravetch JV.

J Exp Med. 2015 Aug 24;212(9):1361-9. doi: 10.1084/jem.20151267. Epub 2015 Aug 17. Review.

21.

Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy.

Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV.

Cell. 2015 Jul 2;162(1):160-9. doi: 10.1016/j.cell.2015.06.026.

22.

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV.

Cell. 2014 Sep 11;158(6):1243-1253. doi: 10.1016/j.cell.2014.08.023.

23.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-999. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

24.

humanized mice to study FcγR function.

Bournazos S, DiLillo DJ, Ravetch JV.

Curr Top Microbiol Immunol. 2014;382:237-48. doi: 10.1007/978-3-319-07911-0_11.

PMID:
25116103
25.

Type I and type II Fc receptors regulate innate and adaptive immunity.

Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV.

Nat Immunol. 2014 Aug;15(8):707-16. doi: 10.1038/ni.2939. Review.

PMID:
25045879
26.

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV.

J Clin Invest. 2014 Feb;124(2):725-9. doi: 10.1172/JCI72676. Epub 2014 Jan 9.

27.

Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J.

J Virol. 2013 Aug;87(15):8535-44. doi: 10.1128/JVI.00868-13. Epub 2013 May 29.

28.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Nature. 2012 Dec 6;492(7427):118-22. doi: 10.1038/nature11604. Epub 2012 Oct 24.

29.

A mouse model for HIV-1 entry.

Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15859-64. Epub 2012 Sep 10.

30.

Mouse model recapitulating human Fcγ receptor structural and functional diversity.

Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6181-6. doi: 10.1073/pnas.1203954109. Epub 2012 Apr 2.

31.

Copy number variation of FCGR3B is associated with susceptibility to idiopathic pulmonary fibrosis.

Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP.

Respiration. 2011;81(2):142-9. doi: 10.1159/000321997. Epub 2010 Nov 27.

32.

Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Bournazos S, Grinfeld J, Alexander KM, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP.

BMC Pulm Med. 2010 Oct 7;10:51. doi: 10.1186/1471-2466-10-51.

33.

Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis.

Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP.

Lung. 2010 Dec;188(6):475-81. doi: 10.1007/s00408-010-9262-3. Epub 2010 Oct 6.

PMID:
20924590
34.

Identification of fibrocytes in peripheral blood.

Bournazos S, Fahim A, Hart SP.

Am J Respir Crit Care Med. 2009 Dec 15;180(12):1279; author reply 1279. No abstract available.

PMID:
19949240
35.

Functional and clinical consequences of Fc receptor polymorphic and copy number variants.

Bournazos S, Woof JM, Hart SP, Dransfield I.

Clin Exp Immunol. 2009 Aug;157(2):244-54. doi: 10.1111/j.1365-2249.2009.03980.x. Review.

36.

Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages.

McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, Dransfield I.

J Immunol. 2009 Aug 1;183(3):2167-75. doi: 10.4049/jimmunol.0803503. Epub 2009 Jul 13.

37.

Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity.

Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I.

J Immunol. 2009 Jun 15;182(12):8026-36. doi: 10.4049/jimmunol.0900107.

38.

Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin.

Bournazou I, Pound JD, Duffin R, Bournazos S, Melville LA, Brown SB, Rossi AG, Gregory CD.

J Clin Invest. 2009 Jan;119(1):20-32. doi: 10.1172/JCI36226. Epub 2008 Dec 1.

39.

Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status.

Bournazos S, Rennie J, Hart SP, Fox KA, Dransfield I.

Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1491-8. doi: 10.1161/ATVBAHA.108.167601. Epub 2008 May 22.

PMID:
18497306
40.

Choice of anticoagulant critically affects measurement of circulating platelet-leukocyte complexes.

Bournazos S, Rennie J, Hart SP, Dransfield I.

Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):e2-3. No abstract available.

PMID:
18094392
41.

A versatile denaturing HPLC approach for human beta-globin gene mutation screening.

Bournazos SN, Tserga A, Patrinos GP, Papadakis MN.

Am J Hematol. 2007 Feb;82(2):168-70.

42.

Defense and melanization depend on the eumelanin pathway, occur independently and are controlled differentially in developing Ceratitis capitata.

Charalambidis ND, Bournazos SN, Lambropoulou M, Marmaras VJ.

Insect Biochem Mol Biol. 1994 Jul;24(7):655-62.

PMID:
8069330

Supplemental Content

Loading ...
Support Center